Cytomegalovirus viraemia in the modern antiretroviral era *

HIV Medicine

Volumn 12, Issue 7, 2011, Pages 387-388

  Jacobson, M A ^a   Lurain, N S ^b   Hunt, P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; VALGANCICLOVIR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM INFECTION; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY T LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HIV-1; HUMANS; MALE; POLYMERASE CHAIN REACTION; VIRAL LOAD; VIREMIA;

EID: 79959942057     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00899.x     Document Type: Editorial

References (10)

1. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998; 101: 497-502.
2. Wohl DA, Kendall MA, Andersen J et al. for the A5030 Study Team. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials 2009; 10: 143-152.
3. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004; 363: 2116-2121.
4. Boffi El Amari E, Combescure C, Yerly S et al. Clinical relevance of cytomegalovirus viraemia. HIV Med 2011; 12: 394-402.
5. Yerly S, Perrin L, Van Delden C et al. Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J Clin Virol 2007; 38: 298-303.
6. Caliendo AM, Ingersoll J, Fox-Canale AM et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 2007; 45: 1723-1727.
7. Hsue PY, Hunt PW, Sinclair E et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20: 2275-2283.
8. Hunt P, Martin J, Sinclair E et al. Valganciclovir reduces CD8+T cell activation among HIV-infected patients with suboptimal CD4+T cell recovery during ART. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2010 [Abstract #380].
9. Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+and CD8+T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673-685.
10. Naeger DM, Martin JN, Sinclair E et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5: e8886.